LLY

1,023.95

+0.54%↑

JNJ

199.13

+0.11%↑

ABBV

233.91

-0.32%↓

UNH

309.9

-5.14%↓

AZN

88.55

-1.44%↓

LLY

1,023.95

+0.54%↑

JNJ

199.13

+0.11%↑

ABBV

233.91

-0.32%↓

UNH

309.9

-5.14%↓

AZN

88.55

-1.44%↓

LLY

1,023.95

+0.54%↑

JNJ

199.13

+0.11%↑

ABBV

233.91

-0.32%↓

UNH

309.9

-5.14%↓

AZN

88.55

-1.44%↓

LLY

1,023.95

+0.54%↑

JNJ

199.13

+0.11%↑

ABBV

233.91

-0.32%↓

UNH

309.9

-5.14%↓

AZN

88.55

-1.44%↓

LLY

1,023.95

+0.54%↑

JNJ

199.13

+0.11%↑

ABBV

233.91

-0.32%↓

UNH

309.9

-5.14%↓

AZN

88.55

-1.44%↓

Strona główna・Stock List・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Open

SectorHealthcare

5.79 -4.14

Buy Sell

Overview

Share price change

24h

Current

Min

5.55

Max

6.04

Key metrics
By Trading Economics
Income	2.1M -7.5M
Profit margin	-33,241.667
Employees	15
EBITDA	4.5M -5.7M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+8.89% upside

Market Stats
By TradingEconomics
Market Cap	90M 335M
Previous open	9.93
Previous close	5.79

News Sentiment

By Acuity

60%

40%

320 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

1.19 / 1.33 Support & Resistance

Galectin Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lis 2025, 18:59 UTC

Major Market Movers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 lis 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 lis 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 lis 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 lis 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 lis 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Rev $2.6B >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q EPS $4.02 >TCOM

17 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Adj EPS 26c >JHX

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 lis 2025, 21:39 UTC

Earnings

James Hardie Industries 2Q Sales $1.29B >JHX

17 lis 2025, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 21:38 UTC

Earnings

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q EPS BRL2.47 >XP

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q Rev BRL4.67B >XP

17 lis 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lis 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 lis 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 lis 2025, 19:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 18:20 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 lis 2025, 16:45 UTC

Acquisitions, Mergers, Takeovers

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 lis 2025, 16:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 16:15 UTC

Earnings

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 lis 2025, 15:40 UTC

Acquisitions, Mergers, Takeovers

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 lis 2025, 15:22 UTC

Acquisitions, Mergers, Takeovers

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 lis 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Comparison

Price change

Galectin Therapeutics Inc Forecast

Price Target

By TipRanks

8.89% upside

12 Months Forecast

Average 6 USD 8.89%

High 6 USD

Low 6 USD

Based on 1 Wall Street analysts offering 12 month price targets forGalectin Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Galectin Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.19 / 1.33Support & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

320 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.